The evolution of assessing bias in Cochrane systematic reviews of interventions: celebrating methodological contributions of the Cochrane Collaboration. by Turner, Lucy et al.
The evolution of assessing bias in Cochrane systematic
reviews of interventions: celebrating methodological
contributions of the Cochrane Collaboration.
Lucy Turner, Isabelle Boutron, Asbjørn Hro´bjartsson, Douglas Altman, David
Moher
To cite this version:
Lucy Turner, Isabelle Boutron, Asbjørn Hro´bjartsson, Douglas Altman, David Moher. The
evolution of assessing bias in Cochrane systematic reviews of interventions: celebrating method-
ological contributions of the Cochrane Collaboration.. Systematic Reviews, BioMed Central,
2013, 2 (1), pp.79. <10.1186/2046-4053-2-79>. <inserm-00871888>
HAL Id: inserm-00871888
http://www.hal.inserm.fr/inserm-00871888
Submitted on 11 Oct 2013
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

COMMENTARY Open Access
The evolution of assessing bias in Cochrane
systematic reviews of interventions: celebrating
methodological contributions of the Cochrane
Collaboration
Lucy Turner1*, Isabelle Boutron2,3,4,5, Asbjørn Hróbjartsson6, Douglas G Altman7 and David Moher1,8
“…to manage large quantities of data objectively and
effectively, standardized methods of appraising
information should be included in review processes.
… By using these systematic methods of exploration,
evaluation, and synthesis, the good reviewer can
accomplish the task of advancing scientific
knowledge”. Cindy Mulrow, 1986, BMJ.
Background
The global evidence base for health care is extensive,
and expanding; with nearly 2 million articles published
annually. One estimate suggests 75 trials and 11 syste-
matic reviews are published daily [1]. Research syntheses,
in a variety of established and emerging forms, are well
recognised as essential tools for summarising evidence
with accuracy and reliability [2]. Systematic reviews pro-
vide health care practitioners, patients and policy makers
with information to help make informed decisions. It is
essential that those conducting systematic reviews are
cognisant of the potential biases within primary studies
and of how such biases could impact review results and
subsequent conclusions.
Rigorous and systematic methodological approaches to
conducting research synthesis emerged throughout the
twentieth century with methods to identify and reduce
biases evolving more recently [3,4]. The Cochrane Colla-
boration has made substantial contributions to the devel-
opment of how biases are considered in systematic
reviews and primary studies. Our objective within this
paper is to review some of the landmark methodological
contributions by members of the Cochrane Bias Methods
Group (BMG) to the body of evidence which guides
current bias assessment practices, and to outline the im-
mediate and horizon objectives for future research
initiatives.
Empirical works published prior to the establishment of
the Cochrane Collaboration
In 1948, the British Medical Research Council published
results of what many consider the first ‘modern’
randomised trial [5,6]. Subsequently, the last 65 years has
seen continual development of the methods used when
conducting primary medical research aiming to reduce in-
accuracy in estimates of treatment effects due to potential
biases. A large body of literature has accumulated which
supports how study characteristics, study reports and pub-
lication processes can potentially bias primary study and
systematic review results. Much of the methodological
research during the first 20 years of The Cochrane Colla-
boration has built upon that published before the Col-
laboration was founded. Reporting biases, or more
specifically, publication bias and the influence of funding
source(s) are not new concepts. Publication bias initially
described as the file drawer problem as a bias concept in
primary studies was early to emerge and has long been
suspected in the social sciences [7]. In 1979 Rosenthal, a
psychologist, described the issue in more detail [8] and
throughout the 1980s and early 1990s an empirical evi-
dence base began to appear in the medical literature
[9-11]. Concurrent with the accumulation of early evi-
dence, methods to detect and mitigate the presence of
publication bias also emerged [12-15]. The 1980s also saw
initial evidence of the presence of what is now referred
to as selective outcome reporting [16] and research in-
vestigating the influence of source of funding on study
results [10,11,17,18].
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The importance of rigorous aspects of trial design (e.g.
randomisation, blinding, attrition, treatment compliance)
were known in the early 1980s [19] and informed the
development by Thomas Chalmers and colleagues of a
quality assessment scale to evaluate the design, imple-
mentation, and analysis of randomized control trials
[20]. The pre-Cochrane era saw the early stages of
assessing quality of included studies, with consideration
of the most appropriate ways to assess bias. Yet, no
standardised means for assessing risk of bias, or “quality”
as it was referred to at the time, were implemented
when The Cochrane Collaboration was established. The
use of scales for assessing quality or risk of bias is cur-
rently explicitly discouraged in Cochrane reviews based
on more recent evidence [21,22].
Methodological contributions of the Cochrane
Collaboration: 1993 – 2013
In 1996, Moher and colleagues suggested that bias assess-
ment was a new, emerging and important concept and
that more evidence was required to identify trial charac-
teristics directly related to bias [23]. Methodological litera-
ture pertaining to bias in primary studies published in the
last 20 years has contributed to the evolution of bias as-
sessment in Cochrane reviews. How bias is currently
assessed has been founded on published studies that pro-
vide empirical evidence of the influence of certain study
design characteristics on estimates of effect, predominately
considering randomised controlled trials.
The publication of Ken Schulz’s work on allocation
concealment, sequence generation, and blinding [24,25]
the mid-1990s saw a change in the way the Collabo-
ration assessed bias of included studies, and it was
recommended that included studies were assessed in re-
lation to how well the generated random sequence was
concealed during the trial.
In 2001, the Cochrane Reporting Bias Methods Group
now known as the Cochrane Bias Methods Group, was
established to investigate how reporting and other biases
influence the results of primary studies. The most sub-
stantial development in bias assessment practice within
the Collaboration was the introduction of the Cochrane
Risk of Bias (RoB) Tool in 2008. The tool was developed
based on the methodological contributions of meta-
epidemiological studies [26,27] and has since been evalu-
ated and updated [28], and integrated into Grading of
Recommendations Assessment, Development and Evalu-
ation (GRADE) [29].
Throughout this paper we define bias as a systematic
error or deviation in results or inferences from the truth
[30] and should not be confused with “quality”, or how
well a trial was conducted. The distinction between in-
ternal and external validity is important to review. When
we describe bias we are referring to internal validity as
opposed to the external validity or generalizability which
is subject to demographic or other characteristics [31].
Here, we highlight landmark methodological publications
which contribute to understanding how bias influences
estimates of effects in Cochrane reviews (Figure 1).
Sequence generation and allocation concealment
Early meta-epidemiological studies assessed the impact of
inadequate allocation concealment and sequence gene-
ration on estimates of effect [24,25]. Evidence suggests
that adequate or inadequate allocation concealment modi-
fies estimates of effect in trials [31]. More recently, several
other methodological studies have examined whether con-
cealment of allocation is associated with magnitude of
effect estimates in controlled clinical trials while avoiding
confounding by disease or intervention [42,46].
More recent methodological studies have assessed the
importance of proper generation of a random sequence
in randomised clinical trials. It is now mandatory, in ac-
cordance with the Methodological Expectations for
Cochrane Interventions Reviews (MECIR) conduct stan-
dards, for all Cochrane systematic reviews to assess po-
tential selection bias (sequence generation and allocation
concealment) within included primary studies.
Blinding of participants, personnel and outcome assessment
The concept of the placebo effect has been considered
since the mid-1950s [47] and the importance of blinding
trial interventions to participants has been well known,
with the first empirical evidence published in the early
1980s [48]. The body of empirical evidence on the influ-
ence on blinding has grown since the mid-1990s, espe-
cially in the last decade, with some evidence highlighting
that blinding is important for several reasons [49]. Cur-
rently, the Cochrane risk of bias tool suggests blinding of
participants and personnel, and blinding of outcome as-
sessment be assessed separately. Moreover consideration
should be given to the type of outcome (i.e. objective or
subjective outcome) when assessing bias, as evidence sug-
gests that subjective outcomes are more prone to bias due
to lack of blinding [42,44] As yet there is no empirical evi-
dence of bias due to lack of blinding of participants and
study personnel. However, there is evidence for studies
described as ‘blind’ or ‘double-blind’, which usually in-
cludes blinding of one or both of these groups of people.
In empirical studies, lack of blinding in randomized trials
has been shown to be associated with more exaggerated
estimated intervention effects [42,46,50].
Different people can be blinded in a clinical trial [51,52].
Study reports often describe blinding in broad terms, such
as ‘double blind’. This term makes it impossible to know
who was blinded [53]. Such terms are also used very in-
consistently [52,54,55] and the frequency of explicit
reporting of the blinding status of study participants and
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personnel remains low even in trials published in top
journals [56], despite explicit recommendations. Blinding
of the outcome assessor is particularly important, both
because the mechanism of bias is simple and foreseeable,
and because evidence for bias is unusually clear [57]. A re-
view of methods used for blinding highlights the variety of
methods used in practice [58]. More research is ongoing
within the Collaboration to consider the best way to con-
sider the influence of lack of blinding within primary stu-
dies. Similar to selection bias, performance and detection
bias are both mandatory components of risk of bias as-
sessment in accordance with the MECIR standards.
Reporting biases
Reporting biases have long been identified as potentially
influencing the results of systematic reviews. Bias arises
when the dissemination of research findings is influenced
by the nature and direction of results, there is still debate
over explicit criteria for what constitutes a ‘reporting bias’.
More recently, biases arising from non-process related is-
sues (i.e. source of funding, publication bias) have been
referred to as meta-biases [59]. Here we discuss the litera-
ture which has emerged in the last twenty years with
regards to two well established reporting biases, non-
publication of whole studies (often simply called publica-
tion bias) and selective outcome reporting.
Publication bias The last two decades have seen a large
body of evidence of the presence of publication bias
[60-63] and why authors fail to publish [64,65]. Given that
it has long been recognized that investigators frequently
fail to report their research findings [66], many more
recent papers have been geared towards methods of de-
tecting and estimating the effect of publication bias. An
array of methods to test for publication bias and additional
recommendations are now available [38,43,67-76], many of
which have been evaluated [77-80]. Automatic generation
of funnel plots have been incorporated when producing a
Cochrane review and software (RevMan) and are en-
couraged for outcomes with more than ten studies [43].
A thorough overview of methods is included in Chapter
10 of the Cochrane Handbook for Systematic Reviews
of Interventions [81].
Selective outcome reporting While the concept of pub-
lication bias has been well established, studies reporting
evidence of the existence of selective reporting of out-
comes in trial reports have appeared more recently
[39,41,82-87]. In addition, some studies have investigated
why some outcomes are omitted from published reports
[41,88-90] as well as the impact of omission of outcomes
on the findings of meta-analyses [91]. More recently,
methods for evaluating selective reporting, namely, the
ORBIT (Outcome Reporting Bias in Trials) classification
system have been developed. One attempt to mitigate se-
lective reporting is to develop field specific core outcome
measures [92] the work of COMET (Core Outcome Mea-
sures in Effectiveness Trials) initiative [93] is supported by
many members within the Cochrane Collaboration. More
research is being conducted with regards to selective
reporting of outcomes and selective reporting of trial ana-
lyses, within this concept there is much overlap with the
movement to improve primary study reports, protocol
development and trial registration.
Evidence on how to conduct risk of bias assessments
Often overlooked are the processes behind how systematic
evaluations or assessments are conducted. In addition to
empirical evidence of specific sources of bias, other met-
hodological studies have led to changes in the processes
used to assess risk of bias. One influential study published
in 1999 highlighted the hazards of scoring ‘quality’ of
Figure 1 Timeline of landmark methods research [8,13,16,17,20,22,26,31-45].
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clinical trials when conducting meta-analysis and is one of
reasons why each bias is assessed separately as ‘high’, ‘low’
or ‘unclear’ risk rather than using a combined score
[22,94]. Prior work investigated blinding of readers,
data analysts and manuscript writers [51,95]. More re-
cently, work has been completed to assess blinding of
authorship and institutions in primary studies when
conducting risk of bias assessments, suggesting that
there is discordance in results between blind and un-
blinded RoB assessments. However uncertainty over
best practice remains due to time and resources needed
to implement blinding [96].
Complementary contributions
Quality of reporting and reporting guidelines
Assessing primary studies for potential biases is a chal-
lenge [97]. During the early 1990s, poor reporting in ran-
domized trials and consequent impediments to systematic
review conduct, especially when conducting what is now
referred to as ‘risk of bias assessment’, were observed. In
1996, an international group of epidemiologists, statisti-
cians, clinical trialists, and medical editors, some of whom
were involved with establishing the Cochrane Collabo-
ration, published the CONSORT Statement [32], a check-
list of items to be addressed in a report of the findings of
an RCT. CONSORT has twice been revised and updated
[35,36] and over time, the impact of CONSORT has been
noted, for example, CONSORT was considered one of the
major milestones in health research methods over the last
century by the Patient-Centered Outcomes Research Insti-
tute (PCORI) [98].
Issues of poor reporting extend far beyond randomized
trials, and many groups have developed guidance to aid
reporting of other study types. The EQUATOR Net-
work’s library for health research reporting includes
more than 200 reporting guidelines [99]. Despite evi-
dence that the quality of reporting has improved over
time, systemic issues with the clarity and transparency of
reporting remain [100,101]. Such inadequacies in pri-
mary study reporting result in systematic review authors’
inability to assess the presence and extent of bias in pri-
mary studies and the possible impact on review results,
continued improvements in trial reporting are needed to
lead to more informed risk of bias assessments in sys-
tematic reviews.
Trial registration
During the 1980s and 1990s there were several calls to
mitigate publication bias and selective reporting via trial
registration [102-104]. After some resistance, in 2004, the
BMJ and The Lancet reported that they would only pub-
lish registered clinical trials [105] with the International
Committee of Medical Journal Editors making a statement
to the same effect [40]. Despite the substantial impact of
trial registration [106] uptake is still not optimal and it is
not mandatory for all trials. A recent report indicated that
only 22% of trials mandated by the FDA were reporting
trial results on clinicaltrials.gov [107]. One study suggested
that despite trial registration being strongly encouraged
and even mandated in some jurisdictions only 45.5% of
a sample of 323 trials were adequately registered [108].
Looking forward
Currently, there are three major ongoing initiatives
which will contribute to how The Collaboration assesses
bias. First, there has been some criticism of the
Cochrane risk of bias tool [109] concerning its ease of
use and reliability [110,111] and the tool is currently be-
ing revised. As a result, a working group is established
to improve the format of the tool, with version 2.0 due
to be released in 2014. Second, issues of study design
arise when assessing risk of bias when including non-
randomised studies in systematic reviews [112-114].
Even 10 years ago there were 114 published tools for
assessing risk of bias in non-randomised studies [115].
An ongoing Cochrane Methods Innovation Fund project
will lead to the release a tool for assessing non-
randomized studies as well as tools for cluster and
cross-over trials [116]. Third, selective reporting in pri-
mary studies is systemic [117] yet further investigation
and adoption of sophisticated means of assessment re-
main somewhat unexplored by the Collaboration. A
current initiative is ongoing to explore optimal ways to
assess selective reporting within trials. Findings of this
initiative will be considered in conjunction with the re-
lease of revised RoB tool and its extension for non-
randomized studies.
More immediate issues
Given the increase in meta-epidemiological research, an
explicit definition of evidence needed to identify study
characteristics which may lead to bias (es) needs to be de-
fined. One long debated issue is the influence of funders
as a potential source of bias. In one empirical study, more
than half of the protocols for industry-initiated trials stated
that the sponsor either owns the data or needs to approve
the manuscript, or both; none of these constraints were
stated in any of the trial publications [118]. It is important
that information about vested interests is collected and
presented when relevant [119].
There is an on-going debate related to the risk of bias
of trials stopping early because of benefit. A systematic
review and a meta-epidemiologic study showed that
such truncated RCTs were associated with greater effect
sizes than RCTs not stopped early, particularly for trials
with small sample size [120,121]. These results were
widely debated and discussed [122] and recommenda-
tions related to this item are being considered.
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In addition, recent meta-epidemiological studies of
binary and continuous outcomes showed that treatment
effect estimates in single-centre RCTs were significantly
larger than in multicenter RCTs even after controlling for
sample size [123,124]. The Bias in Randomized and Ob-
servational Studies (BRANDO) project combining data
from all available meta-epidemiologic studies [44] found
consistent results for subjective outcomes when compa-
ring results from single centre and multi-centre trials. Se-
veral reasons may explain these differences between study
results: small study effect, reporting bias, higher risk of
bias in single centre studies, or factors related to the selec-
tion of the participants, treatment administration and care
providers’ expertise. Further studies are needed to explore
the role and effect of these different mechanisms.
Longer term issues
The scope of methodological research and subsequent
contributions and evolution in bias assessment over the
last 20 years has been substantial. However, there re-
mains much work to be done, particularly in line with
innovations in systematic review methodology itself.
There is no standardised methodological approach to
the conduct of systematic reviews. Subject to a given
clinical question, it may be most appropriate to conduct
a network meta-analysis, scoping review, a rapid review,
or update any of these reviews. Along with the develop-
ment of these differing types of review, there is the need
for bias assessment methods to develop concurrently.
The way in which research synthesis is conducted may
change further with technological advances [125]. Globally,
there are numerous initiatives to establish integrated admin-
istrative databases which may open up new research avenues
and methodological questions about assessing bias when pri-
mary study results are housed within such databases.
Despite the increase in meta-epidemiological research
identifying study characteristics which could contribute to
bias in studies, further investigation is needed. For ex-
ample, as yet there has been little research on integration
of risk of bias results into review findings. This is done in-
frequently and guidance on how to do it could be im-
proved [126]. Concurrently, although some work has been
done, little is known about how magnitude and direction
in estimates of effect for a given bias and across biases for
a particular trial and in turn, set of trials [127].
Conclusion
To summarise, there has been much research conducted to
develop understanding of bias in trials and how these biases
could influence the results of systematic reviews. Much of
this work has been conducted since the Cochrane Collabo-
ration was established either as a direct initiative of the
Collaboration or thanks to the work of many affiliated
individuals. There has been clear advancement in mandatory
processes for assessing bias in Cochrane reviews. These
processes, based on a growing body of empirical evidence
have aimed to improve the overall quality of the systematic
review literature, however, many areas of bias remain un-
explored and as the evidence evolves, the processes used
to assess and interpret biases and review results will also
need to adapt.
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